Redeye comments on Dala Energi’s Q3 report, which presented no real drama, although reported earning...
Redeye provides an initial take on the Q3 2024 report from Precise Biometrics, which is to be consid...
Redeye saw a sales development that was lower than expected.
Redeye updates on Raketech following weaker-than-expected Q3-results.
Redeye provides an update on Thunderful Group following its Q3 2024 report, which was weaker than ex...
Redeye updates its estimates following Surgical Science’s Q3 2024 report, which beat our expectation...
Føroya Banki has a long track record of adapting to market changes.
Comment re-published: we have corrected a factual error.
- Expect weak Q3, revenue recognition from one project - Raise '24e EBIT by SEK 376m & '25e-'26e by ...
Umida Group publicerade den 14 november 2024 bolagets delårsrapport för det tredje kvartalet år 2024...
Även om Cell Impacts utveckling går långsammare än vi tidigare prognostiserat bedömer vi att affärsi...
Redeye has an overall positive impression from the visit to the Hudiksvall factory.
Net sales and EBIT were in line with our estimates.
We lift '24e EBITDA by 27%, '25-'26e up 9-4% Doro now closer to a done deal, could lift '28e EBITA ~...
Redeye comments on Nekkar’s Q3 report that missed our expectations, mainly driven by a lower sales a...
